Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 355-356, 2007; 10.1373/clinchem.2006.078964
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jensen, E.
Right arrow Articles by Hegedüs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, E.
Right arrow Articles by Hegedüs, L.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2007;53:355-356.)
© 2007 American Association for Clinical Chemistry, Inc.


Letters to the Editor

Sampling Time Is Important but May Be Overlooked in Establishment and Use of Thyroid-Stimulating Hormone Reference Intervals

Esther Jensen1,a, Ole Blaabjerg1, Per Hyltoft Petersen2 and Laszlo Hegedüs3

1 Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark
2 NOKLUS, Norwegian quality, improvement of primary care, laboratories, Division for General Practice, University of Bergen, Bergen, Norway
3 Department of, Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

aAddress correspondence to this author at: Department of Clinical Biochemistry, Odense University Hospital, DK-5000 Odense C, Denmark. Fax 45-65-41-19-11; e-mail Esther.Jensen{at}ouh.fyns-amt.dk.


To the Editor:

In the current debate on reference interval(s) for serum thyroid-stimulating hormone (TSH) concentrations, a lowering of the upper reference limit from ~4.0 to 2.5, or even 2.0, mU/L has been proposed by the National Academy of Clinical Biochemistry (NABC) (1). This proposal is based in part on the observation that populations with the lowest prevalence of antithyroid antibodies have the lowest TSH upper limits. Other arguments for the lowering of the upper limit of the reference interval are related to the question of whether mild TSH increases have any clinical consequences. This question, however, illustrates the problem of mixing the concepts of (a) decision limits (e.g., discrimination values, cutoffs, action limits), which are based on the clinical consequences and treatment strategies and (b) reference intervals, which are based solely on biology and mathematics applied in an appropriate reference population. This confusion is also addressed in a recent paper on TSH reference interval(s) (2).

The debate for lowering the upper TSH reference limit also includes the argument that the reference distribution for serum TSH should be gaussian in nature, but the upper tail of the distribution is currently skewed by: (a) euthyroid outliers such as may occur in patients recovering from nonthyroidal illness, (b) measurement of bioinactive TSH isoforms, (c) TSH receptor gene polymorphisms, and (d) occult autoimmune thyroid dysfunction. As a consequence, some authorities suggest the distribution tail to be deleted (1). In our opinion, however, this upper tail is an essential part of the distribution. In fact, when all values from individuals at risk are removed, log-gaussian distributions are common for most serum components (3), as we demonstrated for serum TSH, which is unimodal and log-gaussian (4).

We now focus on the newer documentation regarding serum TSH reference intervals and methods. Despite the fact that several publications suggest an upper limit of ~4 mU/L, NACB proposes an upper limit of 2.5 mU/L, although only one of several population-based studies supports this (Table 1 ).


View this table:
[in this window]
[in a new window]

 
Table 1. Data from recently published studies on TSH reference intervals.

As evidenced in Table 1Up , studies vary widely in time of sampling and analytical methods used, as well as inclusion and exclusion criteria. The study with the highest relative median serum TSH in the Deutschen Gesellschaft für KlinischeChemie und Laboratoriumsmedizin hormone survey could have been expected to demonstrate the highest upper reference limit, but clearly it does not (Table 1Up ), suggesting that factors other than method standardization play a role. Repeated data from external quality assessment performed from 2000 to 2005 disclose that between-method variation is only a minor source of the variation in serum TSH. The exclusion of individuals at risk, however, has been based on nonstandardized criteria, and the importance of time of sampling has been ignored. In fact, in the majority of publications the time of sampling has not been specified.

There is evidence of a considerable diurnal variation in serum TSH concentration, with a maximum around midnight (6). A decrease of up to 50% occurs from 8:00 to 9:30 AM; thereafter the concentration remains relatively constant until evening, with a smaller nadir in the late afternoon. Because serum TSH concentration decreases markedly during the morning and time of sampling is unknown in most studies, sampling time differences between studies may be a primary reason for the discrepancies in published reference intervals. Individuals working night shifts have displaced or reduced diurnal rhythms, a phenomenon that should also be acknowledged (or such individuals excluded) when establishing reference intervals. Consequently, our proposal is to establish reference intervals as a function of time of sampling to reveal the influence of time on reference limits for serum TSH. The outcome of sampling time investigations will indicate whether such data will lead to recommendations for time of sampling or to time-dependent reference intervals.

Studies to establish decision limits for serum TSH should be based on standardized measurements performed in longitudinal follow-up of cohorts with various concentrations of serum TSH. Such studies may well support intervention below a serum TSH concentration of 4.0 mU/L. At present, however, such a decision is not based on unequivocal evidence (2).


References

  1. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Spencer CA, et al. Laboratory Medicine Practice Guidelines: Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  2. Brabant G, Beck-Peccoz P, Jarzab B, Laurberg P, Orgiazzi J, Szabolcs, et al. Is there a need to redefine the upper normal limit of TSH?. Eur J Endocrinol 2006;154:633-637.[Abstract/Free Full Text]
  3. Hyltoft Petersen P, Blaabjerg O, Andersen M, Jorgensen LGM, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004;42:715-724.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  4. Jensen E, Hyltoft Petersen P, Blaabjerg O, Hansen PS, Brix TH, Hegedüs L. Establishment of a serum thyroid stimulating hormone (TSH) reference interval in healthy adults. The importance of environmental factors, including thyroid antibodies. Clin Chem Lab Med 2004;42:824-832.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  5. Deutsche Gesellschaft für Klinische Chemie (DGKL). Ringversuch Hormone survey. HM 2/00 to HM 2/05..
  6. Weeke J, Gundersen HJG. Circadian and 30 minutes variations in serum TSH and thyroid hormones in normal subjects. Acta Endocrinol. (Copenh.) 1978;89:659-672.[Medline] [Order article via Infotrieve]
  7. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.[Abstract/Free Full Text]
  8. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499.[Abstract/Free Full Text]
  9. Kratzsch J, Fiedler GM, Leichtle A, Brügel M, Buchbinder S, Otto L, et al. New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 2005;51:1480-1486.[Abstract/Free Full Text]
  10. Völzke H, Alte D, Kohlmann T, Lüdemann J, Nauck M, John U, et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 2005;15:279-285.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  11. Eskelinen S, Suominen P, Vahlberg T, Löpönen M, Isoaho R, Kivelä SL, et al. The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormones (TSH) and free thyroxine (fT4) in an aged population. Clin Chem Lab Med 2005;43:1380-1385.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  12. d’Herbomez M, Jarrige V, Darte C. Reference intervals for serum thyrotropin (TSH) and free thyroxine (FT4) in adults using the Acces® Immunoassay System. Clin Chem Lab Med 2005;43:102-105.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  13. Surks MI, Goswami G, Daniels GH. Controversy in clinical endocrinology: the thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005;90:5489-5496.[Abstract/Free Full Text]
  14. Hoogendoorn EH, Hermus AR, de Vegt F, Ross HA, Verbeek ALM, Kiemeney LALM, et al. Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem 2006;52:104-111.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Spencer, J. G. Hollowell, M. Kazarosyan, and L. E. Braverman
National Health and Nutrition Examination Survey III Thyroid-Stimulating Hormone (TSH)-Thyroperoxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits May Be Skewed by Occult Thyroid Dysfunction
J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4236 - 4240.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jensen, E.
Right arrow Articles by Hegedüs, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, E.
Right arrow Articles by Hegedüs, L.
Related Collections
Right arrow Endocrinology and Metabolism


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS